The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder
Open Access
- 15 February 2008
- journal article
- research article
- Published by Hindawi Limited
- Vol. 62 (4), 623-632
- https://doi.org/10.1111/j.1742-1241.2008.01711.x
Abstract
The Prevention of Recurrent Episodes of Depression with venlafaxine XR for Two Years trial has reported advantages with maintenance treatment for patients with recurrent depressive disorder. The aim of this study was to assess the cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder, based on a recent clinical trial. A Markov simulation model was constructed to assess the cost-utility of maintenance treatment for 2 years in recurrently depressed patients in Sweden. Risk of relapse and recurrence was based on a recent randomised clinical trial assessing the efficacy and tolerability of maintenance treatment with venlafaxine over 2 years. Costs and quality of life estimations were retrieved from a naturalistic longitudinal observational study conducted in Sweden. Health effects were quantified as quality-adjusted life-years (QALYs). Sensitivity analyses were conducted on key parameters employed in the model. In the base-case analysis, the cost per QALY gained of venlafaxine compared with no treatment was estimated at $18,500 over 2 years. In a probabilistic sensitivity analysis, we found that maintenance treatment with venlafaxine is cost-effective with 90% probability at a willingness to pay per QALY of $67,000 or less. Our long-term analyses also indicate that even under conservative assumptions about future risks of recurrences, maintenance treatment is cost-effective. The present study indicates that maintenance treatment for 2 years with venlafaxine is cost-effective in patients with recurrent major depressive disorder.Keywords
This publication has 35 references indexed in Scilit:
- Resource use and costs associated with patients treated for depression in primary careThe European Journal of Health Economics, 2006
- The Value of Medical Spending in the United States, 1960–2000New England Journal of Medicine, 2006
- Model to assess the cost-effectiveness of new treatments for depressionInternational Journal of Technology Assessment in Health Care, 2006
- Remission from DepressionPharmacoEconomics, 2005
- The Burden of Major Depression Avoidable by Longer-term Treatment StrategiesArchives of General Psychiatry, 2004
- The Economic Burden of Depression in the United StatesThe Journal of Clinical Psychiatry, 2003
- Assessment of Clinical Guidelines for Continuation Treatment in Major DepressionValue in Health, 2001
- Multiple Recurrences of Major Depressive DisorderAmerican Journal of Psychiatry, 2000
- US and UK health economics: Two disciplines separated by a common language?Health Economics, 1998
- Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in FrancePharmacoEconomics, 1998